Welcome to our dedicated page for Paysign SEC filings (Ticker: PAYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Paysign, Inc. filings document formal disclosures for a Nevada public company providing patient affordability programs, donor compensation solutions, engagement and management platforms, and integrated payment processing. Recent Form 8-K reports furnish operating results and financial-condition updates tied to quarterly and annual earnings releases.
The company’s proxy materials describe annual meeting matters, director elections, auditor ratification, board and committee responsibilities, executive compensation, and beneficial ownership of Paysign securities. Other current reports include Regulation FD disclosures related to stockholder derivative action settlement materials, giving the filing record governance, litigation, ownership and reporting-context coverage in addition to financial results.
Paysign, Inc. Chief Financial Officer Jeffery Bradford Baker exercised a derivative award for 60,000 shares on February 28, 2026, receiving 60,000 shares of common stock at a stated price of $0.00 per share. A separate transaction shows 26,055 common shares withheld at $3.55 per share to cover tax obligations linked to the vesting of restricted stock units. After these transactions, Baker directly owned 386,218 shares of Paysign common stock. Footnotes indicate the restricted stock vested in five equal annual installments beginning February 28, 2021 and completing on February 28, 2026.
Paysign, Inc. reported strong Q3 2025 results. Revenue was $21,596,478 (up 41.6% year over year), led by pharma programs at $7,920,604 (up 141.9%) and plasma at $12,860,478 (up 12.4%). Gross margin improved to 56.3%.
Net income was $2,215,135 and diluted EPS was $0.04. Operating income rose to $1,581,951, while interest income contributed $663,666. The effective tax rate was 1.36%. Year-to-date, revenue reached $59,272,980 (up 38.6%) and net income was $6,188,996 (up 153.3%), reflecting higher pharma activity and added plasma centers.
Cash was $7,529,047 with total cash and restricted cash of $118,551,886 at period end. Accounts receivable increased to $49,644,417. The company closed the Gamma Innovation acquisition on March 19, 2025 for $15,558,637, adding $11,071,000 of identifiable intangibles and $4,487,637 of goodwill. Shares outstanding were 55,042,888 as of November 6, 2025.
Paysign, Inc. furnished an 8-K under Item 2.02 to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. Under General Instruction B-2, this information is furnished and not deemed filed under the Exchange Act. Paysign’s common stock trades on Nasdaq under ticker PAYS.
Paysign, Inc. insider Robert Strobo acquired 100,000 shares of restricted common stock on 05/07/2025 at a reported price of $0.00, increasing his beneficial ownership to 347,290 shares. The shares are restricted and will vest in three equal installments: one-third on May 27, 2026, one-third on May 24, 2027, and the final third on May 26, 2028, subject to Strobo's continued service to the company through each vesting date.
The Form 4 was signed by Robert Strobo on 09/26/2025 and identifies his role as Chief Legal Officer and as an officer reporting person. No derivative transactions, dispositions, exercise prices, or additional cash consideration are reported in this filing.
Joan M. Herman, who serves as Executive Vice President, Operations and a director of Paysign, Inc. (PAYS), reported an equity grant on Form 4. On 05/07/2025 she acquired 16,667 shares of restricted common stock at a reported price of $0.000. Following the grant, the filing shows she beneficially owns 838,250 shares in total. The restricted shares vest in three equal installments: 1/3 on May 13, 2026, 1/3 on May 13, 2027 and 1/3 on May 13, 2028, subject to continued service. The Form 4 is signed by Ms. Herman on 09/26/2025.
Paysign, Inc. reported a Form 4 showing that Jeffery Bradford Baker, the company's Chief Financial Officer and a director, was granted 100,000 shares of restricted common stock on 05/07/2025 at a reported price of $0.000. Following the grant, Baker beneficially owns 352,273 shares. The restricted shares vest in three equal installments: one-third on May 29, 2026, one-third on May 20, 2027, and one-third on May 30, 2028, subject to continued service. The Form 4 is signed by Baker on 09/26/2025.
Paysign, Inc. has moved toward resolving several previously reported stockholder derivative lawsuits by entering into a Stipulation and Agreement of Settlement as a nominal defendant. The cases, all in the U.S. District Court for the District of Nevada, alleged securities law violations and related fiduciary claims, and are collectively referred to as the Derivative Actions.
On August 28, 2025, the Court set a final approval hearing for November 14, 2025 at 1:00 p.m. to decide whether the proposed settlement is fair, reasonable, and adequate and to consider any objections. If the Court grants final approval, the settlement will release all claims arising from the Derivative Actions, dismiss the cases with prejudice, and require Paysign to adopt and maintain specified corporate governance reforms. The settlement does not include any admission of fault or wrongdoing, and Paysign states that resolving the claims now is in the best interests of the company and its stockholders given the costs and risks of continued litigation.
Key results (Q2 2025): Total revenues $19,078,353; gross profit $11,755,165; net income $1,387,761; gross margin 61.6%.
Six months YTD: Revenues $37,676,502; net income $3,973,861; gross margin 62.2%. Total assets $193,896,201; total liabilities $151,688,242; cash and restricted cash $113,913,123.
Drivers and transactions: Revenue growth driven by pharma industry (+$5,079,005; +189.9% Q2; +$11,309,014; +223.3% YTD). Plasma revenue declined (-4.7% Q2; -6.9% YTD). On March 19, 2025 Paysign acquired Gamma Innovation LLC: preliminary purchase consideration $15,558,637; identifiable intangible assets $11,071,000; goodwill $4,487,637; earn-out contingent consideration revised to $990,000.